Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bis(5-amidino-2-benzimidazolyl)methane (BABIM) is a synthetic small molecule featuring two benzimidazole rings connected by a methylene bridge and substituted with amidino groups. It belongs to the class of benzimidazole derivatives, which are known for diverse biological activities including antimicrobial, anti-inflammatory, and anticancer effects[3][6]. BABIM has been studied primarily as an experimental inhibitor of serine proteases such as tryptase and trypsin[10]. In preclinical models, it has demonstrated antiviral and antiarthritic properties by inhibiting the replication of certain viruses in mice and reducing inflammation in arthritic rats[10][5]. Its mechanism involves competitive inhibition at the active site of target proteases. The compound is not approved for clinical use but remains a subject of research interest due to its unique structure and potential pharmacological applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bis(5-amidino-2-benzimidazolyl)methane.